Stephen P. Fortmann, MD

Research/Lab website:   Stanford Prevention Research Center

ACTIVE STUDIES

1 RO1 DA017441 (PI Killen); 9/30/03–6/30/08; NIH/NIDA
Behavioral Maintenance Treatment for Smoking Cessation
To examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence.
Role: Co-PI

2 R01 CA67850 (Fortmann); 08/02/05–4/30/09; NIH/NCI
Impact of Retail Tobacco Advertising on Youth Smoking
This project is a longitudinal survey to determine effects of exposure to retail tobacco advertising on smoking initiation.

5 R01 DA017457 (Killen);09/30/03-7/31/09; NIH/NIDA
Selegeline Patch for Treatment of Nicotine Dependence
To conduct the first randomized controlled trial of the efficacy of selegiline patch for the treatment of nicotine dependence.
Role: Co-PI, Medical Director

1 R01 HL87647-01 (PI Quertermous); 09/30/06–07/31/09; NIH
Whole Genome Association for Early Coronary Artery Disease and Related Phenotypes
Among the Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE) cohorts that enrolled cases of coronary disease and disease-free controls across a broad age spectrum, we propose to conduct a whole genome association study on 1,040 subjects followed by a second stage of focused genotyping on a separate sample of 2,093 subjects, as well as replication of the most significant findings with collaborating external investigators.
Role: Investigator

PI (Fortmann); 07/30/07-07/29/08;American Cancer Society, Inc.
Colloquium Series to Discuss an International Tobacco Control Program
The Stanford Global Tobacco Free Research Initiative is currently in its early planning phase. During academic year 2007-2008, it will be sponsoring a series of colloquia presented by international tobacco-control experts.

2 T32 HL07034 Fortmann (PI); 08/1/06 –07/31/11; NIH/NHLBI
Cardiovascular Disease Prevention Training Program
This Training Program is an institutional National Research Service Award with 8 postdoctoral positions; it provides training for behavioral scientists and physicians in interdisciplinary CVD prevention research.

RECENTLY COMPLETED STUDIES

019-01-03-CR (Fortmann); 08/09/04-02/20/07; Kos Pharmaceuticals, Inc.
The Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia: A Dose-ranging Study (SEACOAST Study)
Different dosages of the Simvastatin and Niacin Extended Releas were evaluated for efficacy on plasma lipids.

Fortmann (PI); 10/1/00–09/30/06; Donald W. Reynolds Foundation
Genetic Epidemiology of Cardiovascular Disease and Healthy Aging (PI) [Project 3 of the Donald W. Reynolds Cardiovascular Clinical Research Center at Stanford University (M. Hlatky, PI)]
This was a study of CVD epidemiology that includes case-control association studies for genetic polymorphisms in selected candidate genes and cross-sectional and longitudinal studies of novel risk factors and subclinical CVD in a cohort of healthy men and women aged 60-69.

1R01 CA90300-02 Killen (PI); 05/1/01–04/30/05; NIH/NCI
Maintenance Treatment for Smoking Cessation
This is a placebo-controlled, randomized clinical trial to compare two strategies designed to promote longer-term maintenance of smoking cessation among adult smokers.
Role: Co-PI